🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Nodule IMmunophenotyping Biomarker for Lung Cancer Early Diagnosis Study

Recruitingn/aAges 18 Years - anyAllRoyal Marsden NHS Foundation Trust
NCT05432739 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

NIMBLE is a prospective study for blood biomarker study of lung nodules alongside analysing data which has been collected routinely as part of patient care. The primary aim of NIMBLE is to assess whether artificial intelligence and machine learning based radiomics approaches can be used to distinguish between benign disease and malignancy in a new lung nodule after a previously treated cancer, and where malignant to differentiate between metastatic recurrence or a new primary lung cancer.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients under active investigation or surveillance for incidental lung nodules * Age \> 18. Exclusion Criteria: * Active or previous diagnosis of malignancy (within 5 years preceding baseline scan). * Inability to give informed consent. * Active infection (including tuberculosis or fungal infection). * Clinician-suspected or confirmed active or recent COVID-19 infection (less than 4 weeks before CT scan or required blood sampling date).
💊

What it tests

  • Not listed
📍

Where

9 sites
Barking Havering and Redbridge University Hospitals NHS Trust
Goodmayes, United Kingdom
Calderdale and Huddersfield NHS Foundation Trust
Huddersfield, United Kingdom
Princess Alexandra Hospital
London, United Kingdom
Whittington Health NHS Trust
London, United Kingdom
University College London Hospitals NHS Foundation Trust
London, United Kingdom
Guy's and St Thomas' NHS Foundation Trust
London, United Kingdom
Royal Marsden Hospital
London, United Kingdom
Northumbria NHS Foundation Trust
Newcastle upon Tyne, United Kingdom

…and 1 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy